CYCLERION THERAPEUTICS, INC.

(CYCN)
  Report
Delayed Nasdaq  -  04:00 2022-08-17 pm EDT
0.8444 USD   -7.22%
08/09CYCLERION THERAPEUTICS : Announces CY6463 Clinical Pipeline Progress and Second Quarter 2022 Financial Results - Form 8-K
PU
08/09CYCLERION THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
08/09Cyclerion Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/11/2022 08/12/2022 08/15/2022 08/16/2022 08/17/2022 Date
0.98(c) 0.9299(c) 0.89(c) 0.9101(c) 0.8444 Last
152 204 204 345 102 000 70 918 139 518 Volume
+2.08% -5.11% -4.29% +2.26% -7.22% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 - - -
Net income 2022 -55,7 M - -
Net cash position 2022 22,5 M - -
P/E ratio 2022 -0,78x
Yield 2022 -
Sales 2023 1,10 M - -
Net income 2023 -86,4 M - -
Net cash position 2023 7,83 M - -
P/E ratio 2023 -0,73x
Yield 2023 -
Capitalization 39,6 M 39,6 M -
EV / Sales 2022 -
EV / Sales 2023 28,9x
Nbr of Employees 32
Free-Float 86,5%
More Financials
Company
Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company's lead asset, CY6463, is a central nervous system (CNS)-penetrant, soluble guanylate cyclase (sGC) stimulator that is in clinical development for Alzheimer's disease with vascular pathology (ADv), cognitive impairment associated with schizophrenia (CIAS), and mitochondrial encephalomyopathy, lactic acidosis and stroke-like... 
More about the company
All news about CYCLERION THERAPEUTICS, INC.
08/09CYCLERION THERAPEUTICS : Announces CY6463 Clinical Pipeline Progress and Second Quarter 20..
PU
08/09CYCLERION THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Conditi..
AQ
08/09Cyclerion Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Mo..
CI
08/09Cyclerion Announces CY6463 Clinical Pipeline Progress and Second Quarter 2022 Financial..
GL
07/28CYCLERION THERAPEUTICS : Announces Positive Topline Clinical Data for CY6463 in Patients w..
PU
07/28CYCLERION THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits..
AQ
07/28TRANSCRIPT : Cyclerion Therapeutics, Inc. - Special Call
CI
07/28Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in Patients ..
GL
07/28Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in Patients ..
GL
07/28Cyclerion Therapeutics, Inc. Announces Positive Topline Clinical Data for CY6463 in Pat..
CI
07/27Cyclerion Therapeutics, Inc. - Steven E. Hyman, M.D., Appointed to Cyclerion Therapeuti..
AQ
07/26CYCLERION THERAPEUTICS : Steven E. Hyman, M.D., Appointed to Cyclerion Therapeutics' Board..
PU
07/26CYCLERION THERAPEUTICS, INC. : Change in Directors or Principal Officers, Regulation FD Di..
AQ
07/26Steven E. Hyman, M.D., Appointed to Cyclerion Therapeutics' Board of Directors
GL
07/26Steven E. Hyman, M.D., Appointed to Cyclerion Therapeutics' Board of Directors
GL
More news
News in other languages on CYCLERION THERAPEUTICS, INC.
08/09Cyclerion Therapeutics, Inc. annonce ses résultats pour le deuxième trimestre et le sem..
07/28Cyclerion Therapeutics, Inc. annonce des données cliniques positives pour le CY6463 che..
07/26Cyclerion Therapeutics, Inc. annonce la nomination de Steven E. Hyman, M.D., à son cons..
06/28Cyclerion Therapeutics fournit des données cliniques positives supplémentaires sur le C..
06/17Cyclerion Therapeutics, Inc. annonce des données sur le CY6463 démontrant une améliorat..
More news
Analyst Recommendations on CYCLERION THERAPEUTICS, INC.
More recommendations
Chart CYCLERION THERAPEUTICS, INC.
Duration : Period :
Cyclerion Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CYCLERION THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 0,91 $
Average target price 9,00 $
Spread / Average Target 889%
EPS Revisions
Managers and Directors
Peter M. Hecht Chief Executive Officer & Director
Anjeza Gjino Chief Financial Officer
Marsha H. Fanucci Chairman
Andreas Eugen Busch Chief Scientific Officer
Kevin Durfee Vice President-Information Technology & Facilities
Sector and Competitors
1st jan.Capi. (M$)
CYCLERION THERAPEUTICS, INC.-47.09%40
MODERNA, INC.-33.87%65 706
IQVIA HOLDINGS INC.-13.27%45 640
LONZA GROUP AG-26.68%43 587
SEAGEN INC.10.30%31 450
ALNYLAM PHARMACEUTICALS, INC.34.54%27 384